ChemoCentryx (NASDAQ:CCXI) was upgraded by equities research analysts at JPMorgan Chase & Co. from a “neutral” rating to an “overweight” rating in a research report issued on Thursday, The Fly reports.
CCXI has been the subject of a number of other reports. Canaccord Genuity lowered their price objective on shares of ChemoCentryx from $20.00 to $14.00 and set a “buy” rating for the company in a research report on Thursday, June 6th. Zacks Investment Research lowered shares of ChemoCentryx from a “buy” rating to a “hold” rating in a report on Friday, May 17th. BidaskClub raised shares of ChemoCentryx from a “sell” rating to a “hold” rating in a report on Wednesday, August 21st. Raymond James reduced their target price on shares of ChemoCentryx from $24.00 to $17.00 and set a “strong-buy” rating on the stock in a report on Thursday, June 6th. Finally, ValuEngine raised shares of ChemoCentryx from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. Two investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $18.17.
CCXI stock opened at $7.70 on Thursday. The company has a 50 day simple moving average of $7.11 and a 200 day simple moving average of $10.01. The stock has a market cap of $449.89 million, a price-to-earnings ratio of -10.13 and a beta of 1.19. ChemoCentryx has a 1 year low of $6.16 and a 1 year high of $14.98. The company has a debt-to-equity ratio of 0.28, a current ratio of 3.57 and a quick ratio of 3.57.
ChemoCentryx (NASDAQ:CCXI) last released its quarterly earnings data on Monday, August 5th. The biopharmaceutical company reported ($0.26) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.21) by ($0.05). The company had revenue of $7.17 million for the quarter, compared to analyst estimates of $10.08 million. ChemoCentryx had a negative return on equity of 103.61% and a negative net margin of 144.27%. On average, equities research analysts anticipate that ChemoCentryx will post -1.02 EPS for the current fiscal year.
A number of institutional investors and hedge funds have recently bought and sold shares of CCXI. Tower Research Capital LLC TRC bought a new stake in ChemoCentryx during the 2nd quarter worth approximately $29,000. Quantamental Technologies LLC bought a new stake in shares of ChemoCentryx in the 2nd quarter valued at $46,000. BNP Paribas Arbitrage SA boosted its stake in shares of ChemoCentryx by 46,860.0% in the 1st quarter. BNP Paribas Arbitrage SA now owns 4,696 shares of the biopharmaceutical company’s stock valued at $65,000 after purchasing an additional 4,686 shares during the last quarter. Aperio Group LLC acquired a new position in shares of ChemoCentryx during the 2nd quarter valued at $82,000. Finally, Meeder Asset Management Inc. raised its holdings in ChemoCentryx by 103.5% during the first quarter. Meeder Asset Management Inc. now owns 6,176 shares of the biopharmaceutical company’s stock worth $86,000 after buying an additional 3,141 shares during the last quarter. 64.27% of the stock is currently owned by hedge funds and other institutional investors.
ChemoCentryx Company Profile
ChemoCentryx, Inc, a clinical-stage biopharmaceutical company, develops new medications for inflammatory and autoimmune diseases, and cancer in the United States. The company targets the chemokine and chemoattractant systems to discover, develop, and commercialize orally-administered therapies. Its lead drug candidate is Avacopan, an orally-administered complement inhibitor of the complement C5a receptor (C5aR), is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis.
Recommended Story: What is a growth and income fund?
Receive News & Ratings for ChemoCentryx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChemoCentryx and related companies with MarketBeat.com's FREE daily email newsletter.